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We describe imipenem-resistant and imipenem-susceptible 
clinical isolates of Clostridium difficile ribotype 017 in Portu-
gal. All ribotype 017 isolates carried an extra penicillin-bind-
ing protein gene, pbp5, and the imipenem-resistant isolates 
had additional substitutions near the transpeptidase active 
sites of pbp1 and pbp3. These clones could disseminate 
and contribute to imipenem resistance.
Clostridium difficile, a toxin-producing, spore-forming bacillus, is a main cause of nosocomial antimicrobial 
drug–associated diarrhea in industrialized countries (1). 
C. difficile infection (CDI) usually develops in previously 
hospitalized persons with a recent history of antimicrobial 
drug use and causes illness with symptoms ranging from 
mild diarrhea to potentially lethal pseudomembranous 
colitis (2). Antimicrobial drugs disrupt the protective gut 
microbiota, enabling ingested C. difficile spores to germi-
nate in the colon and providing a selective advantage to 
nonsusceptible strains (3). CDI is mainly mediated by the 
TcdA and TcdB toxins, though some strains additionally 
produce a binary toxin. Multiple antimicrobial drugs can 
promote CDI, and cephalosporins and fluoroquinolones 
have been associated with a higher risk for CDI (3). Mul-
tidrug resistance is frequently found in epidemic C. dif-
ficile strains; determinants of resistance are often found 
in horizontally transferable mobile genetic elements (4). 
In past decades, CDI prominence has increased because 
of a sudden rise in outbreaks and an increase in disease 
severity and death (5). This shift was mainly associated 
with the dissemination of fluoroquinolone-resistant PCR 
ribotype (RT) 027, which has been responsible for hos-
pital outbreaks worldwide. Strains of other ribotypes, 
including RT078 and RT017, which have enhanced 
virulence, have emerged (6). In particular, RT017, the 
most common toxin A–negative, toxin B–positive ribo-
type, is widespread in Asia and is common in Europe (7–
9). In a pan-European study of ≈900 C. difficile strains, 
the overall rate of resistance to imipenem, an antimicrobi-
al drug of the carbapenem class, currently widely used as 
a last-line drug to treat infections by gram-negative bacte-
ria, was found to be 7.41%, and the geometric mean (GM) 
MIC of imipenem for RT017 strains was 5.91 mg/L (8). 
In another study, isolates collected in a South Korea hos-
pital during 2000–2009 were analyzed, and a resistance 
rate to imipenem of 8% (12% among RT017 isolates) 
was found (10).
The Study
We characterized 191 C. difficile isolates collected dur-
ing September 2012–September 2015 from 15 hospitals in 
Portugal (online Technical Appendix, https://wwwnc.cdc.
gov/EID/article/24/4/17-0095-Techapp1.pdf). We found 
24 (12.6%) were resistant to imipenem. Of these 24 iso-
lates, 22 were RT017, 1 was RT014, and 1 was RT477. 
The MIC for imipenem for RT017, the imipenem-resistant 
isolates, was >32 mg/L (Table 1); the MIC for the 2 non-
RT017 isolates was 16 mg/L. The 22 imipenem-resistant 
RT017 isolates were found at hospital A throughout the 
study period, suggesting the existence of a persistent clone, 
a finding supported by whole-genome sequencing data (on-
line Technical Appendix). Among the 25 RT017 isolates, 
3 were imipenem-susceptible and from hospital B (MIC 
range 1.5–3 mg/L) (Table 1).
RT017 C. difficile strains are frequently resistant to 
clindamycin, erythromycin, moxifloxacin, tetracycline, 
or rifampin (individually or in combination) (8,10). In 
this study, the 22 RT017 imipenem-resistant isolates 
were also found to be resistant to all of these antimicro-
bial drugs and showed higher meropenem and ertapenem 
MICs than those of the RT017 imipenem-susceptible 
isolates (Table 1; online Technical Appendix; online 
Technical Appendix Figure). Multidrug resistance to 
noncarbapenem antimicrobial drugs correlated with the 
presence of several genetic determinants, many located 
in mobile genetic elements (Figure 1; online Technical 
Appendix), in line with the idea that multidrug-resistant 
strains have a selective advantage (4) and that horizon-
tal gene transfer plays a major role in the evolution of 
this pathogen (11).
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Through whole-genome sequencing, we found 13 sin-
gle-nucleotide polymorphisms (SNPs) that differentiated 
the imipenem-resistant and imipenem-susceptible RT017 
isolates (Table 2; Figure 1; online Technical Appendix). 
We found 2 SNPs in the genes coding for 2 high molecular 
weight (HMW) penicillin-binding proteins (PBPs) (Fig-
ure 1). HMW PBPs, which are bifunctional enzymes con-
taining transglycosylase and transpeptidase domains, are 
categorized into class A, and PBPs lacking the transgly-
cosylase domain are categorized into class B. The transpep-
tidase domain harbors 3 functional motifs (SXXK, SXN, 
and KTG[T/S]) that comprise the active site. Carbapenems 
block cell wall synthesis by inhibiting transpeptidase activ-
ity (12). One of the mutations found in the imipenem-resis-
tant isolates affected the gene coding for PBP1, the single 
class A bifunctional peptidoglycan synthase of C. diffi-
cile; the mutation resulted in the amino acid substitution 
Ala555Thr close to the SSN functional motif (Figure 2). 
The second mutation was found in the gene encoding for 
the PBP3 class B transpeptidase and caused the amino acid 
replacement Tyr721Ser between the SXN and KTGT mo-
tifs (Figure 2). Neither of these changes was found in the 
3 imipenem-susceptible RT017 isolates (Figure 1). More-
over, the 2 non-RT017 imipenem-resistant isolates, with a 
MIC for imipenem lower than that of the RT017 isolates, 
revealed either the Ala555Thr change or a different substi-
tution (Leu543His), both in PBP1, also close to the func-
tional motif SXN (Table 2). Modified PBPs with reduced 
affinity for the antimicrobial drug have been associated 
with resistance to β-lactams and specifically to imipenem 
in several microorganisms (12). We found no differences 
between the imipenem-resistant and imipenem-susceptible 
RT017 isolates in genes encoding other peptidoglycan 
synthases (Figure 1). It is possible that the substitutions in 
PBP1 and PBP3 in RT017 confer high-level resistance to 
imipenem and reduced susceptibility to other carbapenems, 
and at least in the RT014 and RT477 isolates studied, the 
single Ala555Thr substitution (or other substitutions in the 
vicinity of the SXN motif) is sufficient for an intermediate 
level of resistance.
However, all RT017 isolates studied herein, as well as 
the previously annotated strains M68 (GenBank accession 
no. NC_017175) and BJ08 (accession no. CP003939), 
have a fifth HMW class B PBP, PBP5, encoded in a mo-
bile element (online Technical Appendix). Whether PBP5 
contributes to imipenem resistance remains to be deter-
mined. Moreover, in imipenem-resistant isolates, the key 
sporulation-specific gene sigK, which is contiguous to 
pbp2, is interrupted by the 17-kb skincd element (13), and 
the pbp5 region is contiguous to a transposon-like ele-
ment carrying the ermB gene (shown as PUBMLST allele 
8; https://pubmlst.org/bigsdb?db=pubmlst_cdifficile_se
qdef&page=alleleInfo&locus=ermB&allele_id=8). It is 
unknown whether these genetic differences contribute to 
imipenem resistance.
Conclusions
Imipenem resistance in C. difficile RT017 probably in-
volves the acquisition of mutations in both pbp1 and pbp3 
that lead to amino acid substitutions close to the func-
tional motifs of their transpeptidase domains. These sub-
stitutions might decrease the affinity of PBP1 and PBP3 
for imipenem, enabling peptidoglycan synthesis in the 
presence of the antimicrobial drug. Considering that the 
presence of an additional PBP (PBP5) is a characteris-
tic of RT017 strains, we suggest that PBP5 facilitates the 
expression of imipenem resistance through acquisition of 
mutations in pbp1 and pbp3. In strains of other ribotypes 
lacking PBP5, such as the RT014 and RT477 isolates 
herein described, mutations in pbp1 might only lead to 
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Table 1. Susceptibility of Clostridium difficile RT017 imipenem-resistant isolates from hospital A and imipenem-susceptible isolates 




Antimicrobial drug, MIC breakpoints, mg/L 
IMP‡ ETP‡ MRP‡ MXF†§ MTZ†§ VAN†§ CLI‡ CHL‡ RIF† TGC† TET‡ 
>16 >16 >16 >4 >2 >2 >8 >32 >0.004 >0.25 >16 
A, 22 
isolates 
MIC range >32 3–16 1.5–4 >32 <0.016–1 0.38–2 >256 2–6 >32 <0.016–0.094 16–32 
GM MIC 32 7.56 2.31 32 0.12 0.73 256 3.29 32 0.025 18.08 
MIC90 32 12 3 >32 0.38 2 256 4 32 0.032 32 
MIC50 32 6 2 >32 0.19 0.75 256 3 32 0.023 16 
% Resistant 100 4.5 0 100 0 0 100 0 100 0 100 
B, 3 
isolates 
MIC range 1.5–3 1.5–2 0.5–1.5 1.5 <0.016–0.25 0.38–0.75 >256 3–4 >32 <0.016–0.023 16 
GM MIC 2.08 1.82 0.83 1.5 0.072 0.60 256 3.30 32 0.020 16 
MIC90 3 2 1.5 1.5 0.25 0.75 256 4 32 0.023 16 
MIC50 2 2 0.75 1.5 0.094 0.75 256 3 32 0.023 16 
% Resistant 0 0 0 0 0 0 100 0 100 0 100 
p value  <0.0001 <0.0001 <0.0001 <0.0001 0.45 0.56 ND 0.98 ND 0.41 0.51 
*CHL, chloramphenicol; CLI, clindamycin; ETP, ertapenem; GM, geometric mean; IMP, imipenem; MIC50, minimal inhibitory concentration for 50% of 
strains; MIC90, minimal inhibitory concentration for 90% of strains; MRP, meropenem; MTZ, metronidazole; MXF, moxifloxacin; ND, not done; RIF, 
rifampin; TGC, tigecycline; VAN, vancomycin. 
†European Committee on Antimicrobial Susceptibility Testing breakpoint. 
‡Clinical and Laboratory Standards Institute breakpoint. 
§Previously determined (9). 
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intermediate levels of resistance. We further suggest that 
the spreading of pbp5 might contribute to the dissemina-
tion of high-level imipenem resistance.
Portugal has a high rate of healthcare-associated 
infections and is a major consumer of carbapenems (1). 
Although carbapenem consumption has not been di-
rectly linked to C. difficile resistance, we speculate that 
the emergence of resistance and reduced susceptibility 
to these antimicrobial drugs might recapitulate the sce-
nario observed with fluoroquinolone-resistant RT027 in 
the United States, where fluoroquinolones were the most 
prescribed antimicrobial drug (14). Our findings further 
reinforce the need for the responsible use of antimicrobial 
drugs; the emergence of carbapenem resistance in multi-
drug-resistant C. difficile clones might result in the dis-
semination of resistant strains.
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Figure 1. Phylogeny of Clostridium difficile RT017 isolates from hospitals A and B and genetic determinants of antimicrobial drug 
resistance, Portugal. A) Core genome single-nucleotide polymorphism–based neighbor-joining phylogeny of 25 RT017 C. difficile 
clinical isolates reconstructed by using 47 variant sites (outside MGEs) identified when mapping to either the corresponding 
genomic sequence of close relative C. difficile strain M68 (GenBank accession no. NC_017175) or a draft genome sequence of a 
representative clinical isolate. B) For each isolate, the profile of antimicrobial drug susceptibility is indicated together with respective 
potential genetic determinants of antimicrobial drug resistance. Only antimicrobial drugs for which a resistant phenotype was 
observed are displayed. Gene locus tags are relative to the C. difficile M68 genome annotation. Both nucleotide and amino acid 
replacements refer to mutations in the resistant isolates when comparing with susceptible isolates. No mutations means that no 
mutations are present differentiating resistant isolates of hospital A from susceptible isolates of hospital B, although mutations are 
present relative to M68. Both the pbp5-carrying region and the ermB gene (present in all isolates) were found to be inserted in distinct 
genomic contexts (online Technical Appendix, https://wwwnc.cdc.gov/EID/article/24/4/17-0095-Techapp1.pdf). MSLB, macrolide/
lincosamide/streptogramin B; MGE, mobile genetic element.
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Table 2. Mutations differentiating Clostridium difficile RT017 imipenem-resistant isolates found at hospital A from imipenem-
susceptible isolates found at hospital B, Portugal 







change† Amino acid change† Gene product 
RS02665 512416 C C578T Ala193Val‡ Multidrug ATP-binding cassette transporter permease, 
associated with antimicrobial drug resistance 
RS04280/pbp1 905394 G G1663A Ala555Thr‡ Penicillin-binding transpeptidase 
RS04935 1048151 C T1010C Ile337Thr‡ 3-Isopropylmalate dehydratase large subunit 
RS05670/pbp3 1221182 G A2162C Tyr721Ser‡ Penicillin-binding protein 
RS07765 1666351 G G214T Gly72§ Hypothetical protein 
RS07795/hisB 1671129 T T209C Ile70Thr‡ Imidazoleglycerol-phosphate dehydratase 
RS07810 1673280 T C474T Ala158Ala Imidazoleglycerol-phosphate synthase cyclase subunit 
RS08415 1792079 G A241G Lys81Glu‡ Hypothetical protein (domain of MerR-like 
transcriptional regulators) 
RS08810 1882950 C C420T Asp140Asp Flavodoxin 
RS14235 3083548 G G421T Gly141§ Haloacid dehalogenase 
RS18530 4054525 C C220T Gln74§ S-adenosyl methionine–dependent methyltransferase 
RS19130/gyrA 4174650 C C245T Thr82Ile‡ DNA gyrase subunit A 
RS19545 4255124 C C400T His134Tyr‡ Phage portal, SPP1 Gp6-like family protein 
*Relative to the annotation of the C. difficile M68 genome (GenBank accession no. NC_017175). 
†Changes observed between imipenem-resistant and imipenem-susceptible isolates.  
‡Nonsynonymous mutations. 
§Mutations leading to putative protein truncation. 
 
Figure 2. Amino acid substitutions in 2 PBPs predicted to be associated with imipenem resistance in Clostridium difficile, Portugal.  
The domains and conserved motifs SXXK, SXN, and KTG[T/S] are shown for the following proteins: PBP1 (A), homolog of  
CDM68_RS04280 of RT017 strain M68 (GenBank accession no. NC_017175) or CD630_07810 in the laboratory strain 630; and PBP3 
(B), homolog of CDM68_RS05670 or CD630_11480. The mutations found in these resistant isolates are marked by red lines. The 
alignments below the 2 proteins show the position (shaded in pink) and nature of the amino acid substitutions observed in the imipenem-
resistant RT017 isolates and select PBPs from microorganisms Staphylococcus aureus (GenBank accession no. AAA74375.1), 
Streptococcus pneumoniae (GenBank accession no. WP_001829432.1), Escherichia coli (GenBank accession no. AAB40835.1), 
Enterococcus faecalis (GenBank accession no. AAS77615.1), and Enterococcus faecacium (GenBank accession no. AIG13039.1). The 
conserved motifs in the vicinity of the substitutions are shaded in blue. PBP, penicillin-binding protein; TGase, transglycosylase; TM, 
transmembrane; TPase, transpeptidase.
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